Multiple Myeloma Drugs Market Present Chances, Trends, Value Chain And Stakeholder Analysis 2018-2026
Multiple
Myeloma is a form of cancer formed by malignant plasma cells.
Malignant tumors are formed from highly unstable abnormal cells
travelling via the blood stream, circulatory system, and lymphatic
system. The plasma cells become cancerous and vigorously
proliferative, producing tumor called plasmacytoma that prevents the
bone marrow from producing healthy blood cells and immunoglobulins.
The formation and proliferation of myeloma cells result in fewer
leukocyte, erythrocyte, and platelet cell formation causing a damaged
immune system. Gastrointestinal problems, enlarged organs, kidney
damage, rapid weight loss, bone pain, and fever are some of the
common symptoms of multiple myeloma. Multiple myeloma is considered
to be the third most common blood cancer followed by lymphoma and
leukemia.
Request
Sample Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/839
Introduction
of monoclonal antibodies with safety profile to fight myeloma cells
is expected to drive themultiple myeloma drugs market
The
increasing microRNA therapeutics, nanomedicine platform emergence,
and constant introduction of effective and safe therapeutics drives
the growth of multiple myeloma drugs market. The drugs market is
expected to gain momentum with the addition of monoclonal antibodies
and Histone Deacetylase (HDAC) inhibitors to the current therapeutics
array. The biologic therapy of monoclonal antibodies including
DARZALEX and EMPLICITI are largely preferred by the physicians owing
to the established clinical profile. The growing prevalence of the
disorder with the surging elderly population, the inefficiency of the
current medication augments to invest in research and development,
thereby driving the global market in the forecast period.
Additionally, the supportive treatment demand for restoration
procedures including point of care technologies, approved safety
profile and efficiency of monoclonal antibodies is expected to
broaden the drug treatment received by the patients.
Novel
targeted therapy segment is expected to fuel the multiple myeloma
drugs market
The
global multiple myeloma drugs market is segmented on the basis of
technology, diagnosis, surgery, end user and geography.
On
the basis of drug type, the global multiple myeloma drugs market is
segmented into:
-
Immunomodulating agents
-
Proteasome inhibitors
-
Histone Deacetylase (HDAC) inhibitors
-
Steroids (Corticosteroids)
-
Monoclonal antibodies
On
the basis of distribution channel, the global multiple myeloma drugs
market is segmented into:
-
Hospital Pharmacy
-
Retail Pharmacy
-
ePharmacies
Presence
of major key players accounts for the drastic dominance of Europe in
the global multiple myeloma drugs market
Regional
segmentation of the global mouth ulcers treatment market by Coherent
Market Insights comprises North America, Europe, Asia Pacific, Latin
America, The Middle East and Africa. According to the American Cancer
Society’s estimates for 2017, about 30,280 new cases will be
diagnosed including 17,490 in men and 12,790 in women in the U.S.,
with an expected 12,590 deaths, thus indicating rising prevalence of
multiple myeloma cases in North America with the rise in effective
treatment. Also, North America is expected to dominate the multiple
myeloma drugs market owing to change in lifestyle habits, obesity,
and the launch of various multiple myeloma therapies. For instance,
the launch of NINLARO, DARZALEX, and FARYDAK will considerably drive
the growth of the market in the forecast period. The European market
is expected to rise drastically owing to the presence of major
players, favorable reimbursement policies. and immediate FDA drug
approval rates.
Launching
drugs due to high unmet medical needs of patients is a strategy
adopted by key players
Key
players operating the global multiple myeloma drugs market include
Novartis, Johnson & Johnson,
Elgene, Takeda Pharmaceuticals, and Amgen. The strategies
adopted by the key players include advances in research
activities, the launch of novel therapies specific for effective
treatment due to unmet medical needs increase the competition among
vendors. Other leading vendors include Acceleron Pharma,
Bristol-Meyer Squibb, Sanofi, GlaxoSmithKline, and Merck.
Click
to read more on Multiple
Myeloma Drugs Market
About
Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment